Centessa Pharmaceuticals plc(CNTA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CNTA Centessa Pharmaceuticals plc

Trading 01-07 12:01:50 EST

22.80

+0.12

+0.53%

High23.69	Low22.70	Vol275.78K
Open22.70	D1 Closing22.68	Amplitude4.37%
Mkt Cap3.33B	Tradable Cap2.21B	Total Shares146.00M
T/O6.35M	T/O Rate0.28%	Tradable Shares97.13M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CNTA","market":"US","secType":"STK","nameCN":"Centessa Pharmaceuticals plc","latestPrice":22.8,"timestamp":1767805303125,"preClose":22.68,"halted":0,"volume":275777,"delay":0,"floatShares":97125800,"shares":146000000,"eps":-1.821169,"marketStatus":"Trading","change":0.12,"latestTime":"01-07 12:01:50 EST","open":22.7,"high":23.69,"low":22.7,"amount":6352335.66664,"amplitude":0.043651,"askPrice":22.83,"askSize":275,"bidPrice":22.8,"bidSize":269,"shortable":3,"etf":0,"ttmEps":-1.821169,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1767819600000},"marketStatusCode":2,"adr":0,"adrRate":1,"listingDate":1622174400000,"exchange":"NASDAQ","adjPreClose":22.68,"preHourTrading":{"tag":"盘前","latestPrice":23,"preClose":22.68,"latestTime":"09:23 EST","volume":94,"amount":2134.1901,"timestamp":1767795838607},"postHourTrading":{"tag":"盘后","latestPrice":22.68,"preClose":22.68,"latestTime":"19:34 EST","volume":9924,"amount":225071.68,"timestamp":1767746044235},"volumeRatio":0.427945,"impliedVol":0.7843,"impliedVolPercentile":0.372},"requestUrl":"/m/hq/s/CNTA","defaultTab":"news","newsList":[{"id":"2601874714","title":"Centessa Pharmaceuticals Issues Amended UK Employment Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2601874714","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601874714?lang=en_us&edition=fundamental","pubTime":"2026-01-07 19:01","pubTimestamp":1767783698,"startTime":"0","endTime":"0","summary":"Centessa Pharmaceuticals plc has issued an amendment to its UK Employment Agreement with Mario Alberto Accardi, effective January 1, 2026. The amended agreement supersedes all prior agreements between Accardi and the company, including his previous employment agreement with Orexia Limited.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Centessa Pharmaceuticals plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 07, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nNDL9JcLRy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","BK4139","CNTA","BK4539"],"gpt_icon":0},{"id":"2600736063","title":"Centessa Pharmaceuticals Is Maintained at Buy by Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2600736063","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600736063?lang=en_us&edition=fundamental","pubTime":"2026-01-02 20:59","pubTimestamp":1767358740,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CNTA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 02, 2026 07:59 ET (12:59 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNTA","BK4139","BK4539","BK4535"],"gpt_icon":0},{"id":"2590951542","title":"Centessa Pharmaceuticals PLC - Appoints Mario Alberto Accardi As CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2590951542","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590951542?lang=en_us&edition=fundamental","pubTime":"2025-12-11 20:55","pubTimestamp":1765457719,"startTime":"0","endTime":"0","summary":"Dec 11 (Reuters) - Centessa Pharmaceuticals PLC <260y.F>::*CENTESSA PHARMACEUTICALS PLC - APPOINTS MARIO ALBERTO ACCARDI AS CEO*CENTESSA PHARMACEUTICALS PLC - SAURABH SAHA TO STEP DOWN AS CEO EFFECTIV","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nRSD43vmww:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","BK4139","BK4539","CNTA"],"gpt_icon":0},{"id":"2590513140","title":"Centessa Pharmaceuticals Names Mario Alberto Accardi CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2590513140","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590513140?lang=en_us&edition=fundamental","pubTime":"2025-12-11 20:23","pubTimestamp":1765455816,"startTime":"0","endTime":"0","summary":"Centessa Pharmaceuticals (CNTA) said Thursday the board has appointed Mario Alberto Accardi, president and founder of its Orexin program, as chief executive officer, effective Jan. 1.Accardi will succeed Saurabh Saha, who will step down and be appointed the CEO's adviser, the company said.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK4535","CNTA","BK4539"],"gpt_icon":0},{"id":"2590518108","title":"Press Release: Centessa Pharmaceuticals Announces CEO Transition as Company Advances Strategy to Extend Orexin Leadership into Multiple Neuroscience Indications","url":"https://stock-news.laohu8.com/highlight/detail?id=2590518108","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590518108?lang=en_us&edition=fundamental","pubTime":"2025-12-11 20:00","pubTimestamp":1765454400,"startTime":"0","endTime":"0","summary":"BOSTON and LONDON, Dec. 11, 2025  -- Centessa Pharmaceuticals plc , a clinical-stage pharmaceutical company, today announced that its Board of Directors has appointed Mario Alberto Accardi PhD, President and founder of Centessa's Orexin Program, as Chief Executive Officer  and member of the Board, effective January 1, 2026. Dr. Accardi will succeed Saurabh Saha MD PhD, who will step down from his position as CEO and a member of the Board, effective January 1, 2026. Dr. Saha will be appointed advisor to the CEO.\"OX2R agonists represent one of the most compelling growth opportunities in neuroscience, and Centessa's leading orexin franchise is well-positioned to capitalize on this potential,\" said Dr. Accardi. \"ORX750, our most advanced OX2R agonist, has already demonstrated a potential best-in-class profile for narcolepsy and idiopathic hypersomnia, with","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IH","CNTA","BK4539","BK4563","BK4535","BK4510","BK4139","BK4085","CEO"],"gpt_icon":0},{"id":"2590837893","title":"Centessa Pharmaceuticals President Mario Alberto Accardi Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2590837893","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590837893?lang=en_us&edition=fundamental","pubTime":"2025-12-10 08:08","pubTimestamp":1765325296,"startTime":"0","endTime":"0","summary":"Mario Alberto Accardi, President, Orexin Program, reported a disposal of common shares of Centessa Pharmaceuticals plc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Centessa Pharmaceuticals plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 09, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nNDL70837p:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Centessa Pharmaceuticals President Mario Alberto Accardi Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","BK4139","BK4539","CNTA"],"gpt_icon":0},{"id":"2590364311","title":"Mario Alberto Accardi, President of Orexin Program, sells common shares of Centessa Pharmaceuticals plc","url":"https://stock-news.laohu8.com/highlight/detail?id=2590364311","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590364311?lang=en_us&edition=fundamental","pubTime":"2025-12-09 07:26","pubTimestamp":1765236398,"startTime":"0","endTime":"0","summary":"Mario Alberto Accardi, President of the Orexin Program at Centessa Pharmaceuticals plc, reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Centessa Pharmaceuticals plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 08, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDL2X6vVL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Mario Alberto Accardi, President of Orexin Program, sells common shares of Centessa Pharmaceuticals plc","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNTA","BK4539","BK4535","BK4139"],"gpt_icon":0},{"id":"2589432528","title":"13D Filings -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2589432528","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589432528?lang=en_us&edition=fundamental","pubTime":"2025-12-06 07:35","pubTimestamp":1764977700,"startTime":"0","endTime":"0","summary":"These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities. Subsequent changes in holdings or intentions must be reported in amended filings. This material is from Nov. 27 through Dec. 3, 2025. Source: VerityData. Insight Enterprises ValueAct Capital lowered its stake in the enterprise information-technology company to 1,446,739 shares. ValueAct Capital did so through the sale of 220,000 Insight Enterprises shares from Oct. 29 through Dec. 1 at per share prices ranging from $85 to $105.09. Following the latest sales, ValueAct Capital continues to own 4.7% of Insight Enterprises' outstanding stock, placing ValueAct below the 5% threshold that would require it to report further sales. Shares of Insight Enterprises have lost approximately 40.6% of their value since the beginning of this","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4595","BK4139","USDT.USD.CC","DNTH","NSIT","BK4140","BK4535","USDT.USD.HKCC","BK4109","ASH","CNTA","BK4023","BK4600","LU2463526074.USD","BK4539","BTDR"],"gpt_icon":0},{"id":"2588722805","title":"Centessa Pharmaceuticals Plc : B. Riley Raises Target Price to $42 From $33","url":"https://stock-news.laohu8.com/highlight/detail?id=2588722805","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588722805?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:07","pubTimestamp":1764590826,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nFWN3X70FW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4539","CNTA","BK4535"],"gpt_icon":0},{"id":"2584692484","title":"Centessa Pharmaceuticals Announces Pricing Of $250,000,000 Public Offering Of American Depositary Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2584692484","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584692484?lang=en_us&edition=fundamental","pubTime":"2025-11-20 01:22","pubTimestamp":1763572939,"startTime":"0","endTime":"0","summary":"Centessa Pharmaceuticals PLC <260y.F>::*CENTESSA PHARMACEUTICALS ANNOUNCES PRICING OF $250,000,000 PUBLIC OFFERING OF AMERICAN DEPOSITARY SHARES*CENTESSA PHARMACEUTICALS PLC  - PRICING OF 11.6 MILLION","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSDbHMQjJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNTA","BK4535","BK4539","BK4139"],"gpt_icon":0},{"id":"2584716965","title":"Iqbal J. Hussain, General Counsel, reports disposal of Centessa Pharmaceuticals plc common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2584716965","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584716965?lang=en_us&edition=fundamental","pubTime":"2025-11-19 05:18","pubTimestamp":1763500728,"startTime":"0","endTime":"0","summary":"Iqbal J. Hussain, General Counsel of Centessa Pharmaceuticals plc, reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Centessa Pharmaceuticals plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 18, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nNDL4MktT8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Iqbal J. Hussain, General Counsel, reports disposal of Centessa Pharmaceuticals plc common shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4535","CNTA","BK4539"],"gpt_icon":0},{"id":"2584966844","title":"Centessa Pharmaceuticals Chief Technology & Quality Officer Tia L. Bush Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2584966844","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584966844?lang=en_us&edition=fundamental","pubTime":"2025-11-19 05:17","pubTimestamp":1763500667,"startTime":"0","endTime":"0","summary":"Tia L. Bush, Chief Technology & Quality Officer of Centessa Pharmaceuticals plc, has reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Centessa Pharmaceuticals plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 18, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nNDL8hj0P7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","BK4139","CNTA","BK4539"],"gpt_icon":0},{"id":"2584493453","title":"Centessa price target raised to $43 from $28 at Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2584493453","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584493453?lang=en_us&edition=fundamental","pubTime":"2025-11-18 19:55","pubTimestamp":1763466928,"startTime":"0","endTime":"0","summary":"Guggenheim raised the firm’s price target on Centessa (CNTA) to $43 from $28 and keeps a Buy rating on the shares following the “promising” prelimi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/centessa-price-target-raised-to-43-from-28-at-guggenheim-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/centessa-price-target-raised-to-43-from-28-at-guggenheim-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","CNTA","BK4139","BK4535"],"gpt_icon":0},{"id":"2584967389","title":"Centessa Pharmaceuticals, CG Oncology Drive Q3 Biotech Momentum, Morgan Stanley Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2584967389","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584967389?lang=en_us&edition=fundamental","pubTime":"2025-11-18 01:38","pubTimestamp":1763401110,"startTime":"0","endTime":"0","summary":"Centessa Pharmaceuticals (CNTA), CG Oncology (CGON) and Contineum Therapeutics (CTNM) delivered a series of clinical and financial updates in Q3, standing out as key outperformers on rising confidence","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00BZ1G4Q59.USD","LU1244550221.USD","BK4539","BK4611","LU0006306889.USD","BK4127","LU0234570918.USD","LU1989772840.SGD","LU2023251221.USD","LU1720051108.HKD","CNTA","LU1162221912.USD","DNLI","LU1244550494.USD","LU2089284900.SGD","LU0795875086.SGD","BK4585","BK4139","LU0098860793.USD","LU0106261372.USD","LU1074936037.SGD","BK4609","IE00BGHQF748.EUR","BK4007","BK4516","LU0971096721.USD","IE00BKVL7J92.USD","LU0106831901.USD","BK4504","LU2111349929.HKD","BK4534","LU2028103732.USD","IE00B64PRP62.GBP","CTNM","LU1720051017.SGD","LU1732800096.USD","CGON","LU0795875169.SGD","LU2347655156.SGD","LU1668664300.SGD","IE00B3QW5Z07.USD","LU2133065610.SGD","BK4535","LU1244550577.SGD","CG","LU0557290698.USD","LU1732799900.SGD","LU0267386448.USD","LU0882574139.USD"],"gpt_icon":1},{"id":"2584962884","title":"Morgan Stanley Raises Price Target on Centessa Pharmaceuticals to $36 From $27, Keeps Overweight Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2584962884","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584962884?lang=en_us&edition=fundamental","pubTime":"2025-11-17 20:07","pubTimestamp":1763381263,"startTime":"0","endTime":"0","summary":"Centessa Pharmaceuticals's (CNTA) US stock has an average rating of buy and mean price target of $35.23, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic res","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4535","BK4539","BK4139","CNTA"],"gpt_icon":0},{"id":"2583631730","title":"Centessa Pharmaceuticals (CNTA) Raises $250 Million for Pipeline Expansion Is This a Turning Point?","url":"https://stock-news.laohu8.com/highlight/detail?id=2583631730","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583631730?lang=en_us&edition=fundamental","pubTime":"2025-11-15 11:33","pubTimestamp":1763177629,"startTime":"0","endTime":"0","summary":"Centessa Pharmaceuticals recently completed a significant follow-on equity offering, raising approximately US$250 million through the sale of more than 11.6 million American Depositary Shares at US$21.50 each, with additional purchase options granted to underwriters.\nThis capital raise follows a period of increased research and development spending, with proceeds aimed at supporting the advancement of Centessa’s diverse pipeline targeting neurological and neuropsychiatric disorders.\nWe'll...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cnta/centessa-pharmaceuticals/news/centessa-pharmaceuticals-cnta-raises-250-million-for-pipelin","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cnta/centessa-pharmaceuticals/news/centessa-pharmaceuticals-cnta-raises-250-million-for-pipelin","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CNTA","BK4535","BK4075","BK4539","BK4139","TPB"],"gpt_icon":0},{"id":"2583526848","title":"Centessa Pharmaceuticals (CNTA): Assessing Valuation After a 44% Three-Month Share Price Surge","url":"https://stock-news.laohu8.com/highlight/detail?id=2583526848","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583526848?lang=en_us&edition=fundamental","pubTime":"2025-11-14 10:21","pubTimestamp":1763086898,"startTime":"0","endTime":"0","summary":"Centessa Pharmaceuticals (CNTA) has seen its shares climb an impressive 44% in the past 3 months, drawing attention from investors looking for growth stories in biotech. This strong move invites a deeper look at what is driving sentiment lately.\nSee our latest analysis for Centessa Pharmaceuticals.\nMomentum has been building for Centessa Pharmaceuticals, with a sharp 90-day share price return of nearly 44% and a stellar 633% total shareholder return over three years. These gains reflect...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cnta/centessa-pharmaceuticals/news/centessa-pharmaceuticals-cnta-assessing-valuation-after-a-44","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cnta/centessa-pharmaceuticals/news/centessa-pharmaceuticals-cnta-assessing-valuation-after-a-44","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CNTA","BK4539","BK4139","BK4535"],"gpt_icon":0},{"id":"2583351037","title":"Centessa Pharmaceuticals Chief Technology & Quality Officer Tia L. Bush Reports Common Share Disposal","url":"https://stock-news.laohu8.com/highlight/detail?id=2583351037","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583351037?lang=en_us&edition=fundamental","pubTime":"2025-11-14 06:03","pubTimestamp":1763071387,"startTime":"0","endTime":"0","summary":"Tia L. Bush, Chief Technology & Quality Officer of Centessa Pharmaceuticals plc, has reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Centessa Pharmaceuticals plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 13, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDL3RCgnJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Centessa Pharmaceuticals Chief Technology & Quality Officer Tia L. Bush Reports Common Share Disposal","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNTA","BK4539","BK4535","BK4139"],"gpt_icon":0},{"id":"2583304423","title":"Sector Update: Health Care Stocks Higher in Afternoon Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2583304423","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583304423?lang=en_us&edition=fundamental","pubTime":"2025-11-13 03:11","pubTimestamp":1762974715,"startTime":"0","endTime":"0","summary":"Health care stocks rose Wednesday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund  each adding 1.5%.The iShares Biotechnology ETF  increased 0.6%.In corporate news, AbbVie  is terminating its decade-long partnership with Calico Life Sciences, an Alphabet-backed  biotech company dedicated to aging research, STAT+ reported Wednesday, citing internal emails it viewed. AbbVie shares were rising 3.8%.Centessa Pharmaceuticals  shares jumped 17% in recent Wednesday trading, a day after the company priced its public offering of 11.6 million American depositary shares, each representing one ordinary share, at $21.50 apiece, for expected gross proceeds of about $250 million.Bristol-Myers Squibb  and the Sarah Cannon Research Institute have expanded their strategic collaboration, aiming to accelerate the development of cancer therapies and to increase clinical trial access for US patients, the company and the institute said Wednesday. Bristol-Myers shares ad","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"39f842aaca0a9e2fc2dc7989bdbcde7e","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0048584097.USD","LU0320765059.SGD","IBB","EVO.AU","LU0310799852.SGD","CNTA","LU0052756011.USD","LU1670710588.SGD","LU1221951046.USD","BK4514","LU0889566641.SGD","LU2087625088.SGD","XLV","BMY","LU2357305700.SGD","LU1670628061.USD","LU1839511570.USD","LABU","LU1642822529.SGD","LU1880398471.USD","LU1934455863.HKD","LU2112291526.USD","LU2129689431.USD","LU2129689514.USD","LU0640476718.USD","LU1145028129.USD","ABBV","XBI","LU2860962120.EUR","LU2468319806.SGD","LU0528227936.USD","LU1366192091.USD","USJW.SI","BK4077","EVO","LU2089284900.SGD","LU2129689605.HKD","LU1221951129.SGD","LU1366333091.USD","LU1815333072.USD","SG9999015952.SGD","LU0157215616.USD","LU0965508806.USD","LU0029864427.USD","LU1585245621.USD","LU1496350171.SGD","IE0004445015.USD","LU1548497426.USD"],"gpt_icon":1},{"id":"2583067233","title":"Centessa rises 14.0%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583067233","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583067233?lang=en_us&edition=fundamental","pubTime":"2025-11-13 01:05","pubTimestamp":1762967136,"startTime":"0","endTime":"0","summary":"Centessa (CNTA) is up 14.0%, or $3.15 to $25.69. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial ne...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/centessa-rises-14-0-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/centessa-rises-14-0-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4535","CNTA","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.centessa.com","stockEarnings":[{"period":"1week","weight":-0.0833},{"period":"1month","weight":-0.2417},{"period":"3month","weight":0.017},{"period":"6month","weight":0.5481},{"period":"1year","weight":0.3548},{"period":"ytd","weight":-0.0932}],"compareEarnings":[{"period":"1week","weight":0.007},{"period":"1month","weight":0.0089},{"period":"3month","weight":0.0278},{"period":"6month","weight":0.1054},{"period":"1year","weight":0.162},{"period":"ytd","weight":0.0145}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.016512},{"month":2,"riseRate":0.25,"avgChangeRate":0.004574},{"month":3,"riseRate":0.75,"avgChangeRate":0.02482},{"month":4,"riseRate":0.25,"avgChangeRate":-0.009467},{"month":5,"riseRate":0,"avgChangeRate":-0.150221},{"month":6,"riseRate":0.8,"avgChangeRate":0.098968},{"month":7,"riseRate":0.6,"avgChangeRate":0.113087},{"month":8,"riseRate":0.6,"avgChangeRate":0.057921},{"month":9,"riseRate":0.4,"avgChangeRate":0.033671},{"month":10,"riseRate":0.6,"avgChangeRate":0.00007},{"month":11,"riseRate":0.6,"avgChangeRate":-0.006712},{"month":12,"riseRate":0.2,"avgChangeRate":-0.030273}],"exchange":"NASDAQ","name":"Centessa Pharmaceuticals plc","nameEN":"Centessa Pharmaceuticals plc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Centessa Pharmaceuticals plc(CNTA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Centessa Pharmaceuticals plc(CNTA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Centessa Pharmaceuticals plc,CNTA,Centessa Pharmaceuticals plc股票,Centessa Pharmaceuticals plc股票老虎,Centessa Pharmaceuticals plc股票老虎国际,Centessa Pharmaceuticals plc行情,Centessa Pharmaceuticals plc股票行情,Centessa Pharmaceuticals plc股价,Centessa Pharmaceuticals plc股市,Centessa Pharmaceuticals plc股票价格,Centessa Pharmaceuticals plc股票交易,Centessa Pharmaceuticals plc股票购买,Centessa Pharmaceuticals plc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Centessa Pharmaceuticals plc(CNTA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Centessa Pharmaceuticals plc(CNTA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction